Compare Cytokinetics Inc (CYTK) vs Invesco WilderHill Clean Energy ETF (PBW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Invesco WilderHill Clean Energy ETF — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Invesco WilderHill Clean Energy ETF trades at $28.29 (market cap $347.46M). The key difference: Cytokinetics Inc is far larger — about 24.5× Invesco WilderHill Clean Energy ETF's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Invesco WilderHill Clean Energy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Invesco WilderHill Clean Energy ETF for 46 Days on average.
| CYTK | PBW | |
|---|---|---|
Market Cap | $8.50B | $347.46M |
Volume | 2,395,556 | 413,698 |
Sector | Health | Sector/Thematic |
52-Week High | $87.26 | $46.99 |
52-Week Low | $54.76 | $28.29 |
Typical Hold Time | 19 Days | 46 Days |
Enterprise Value | $8.60B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
PBW, the Invesco WilderHill Clean Energy ETF, trades at $28.92, down 2.89% today amid a bearish technical signal from moving averages. The ETF's unique selection criteria prioritize ecological factors over financial metrics, resulting in concentrated exposure to the clean energy sector. Recent institutional selling, including a 96.3% reduction by IFP Advisors Inc. in Q2 2026 (SEC filing, September 18, 2026), reflects cautious sentiment despite long-term growth drivers like energy security and data center demand.
Outlook remains challenged by near-term volatility and sector underperformance versus broad markets, though global investment in clean energy offers structural tailwinds. Key risks include oil price swings, Fed policy impacts, and lack of diversification. Investors face a trade-off between speculative growth potential and elevated sensitivity to macroeconomic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →
